Ayvakit

Blueprint's Ayvakit picks up long-awaited FDA approval in indolent systemic mastocytosis
Blueprint's Ayvakit picks up long-awaited FDA approval in indolent systemic mastocytosis
Fierce Pharma
Blueprint Medicines
Ayvakit
FDA
indolent systemic mastocytosis
systemic mastocytosis
Flag link:
Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label
Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label
Endpoints
Blueprint Medicines
FDA
Ayvakit
systemic mastocytosis
Flag link:
Blueprint gears up for Ayvakit expansion, with blockbuster sales on the line
Blueprint gears up for Ayvakit expansion, with blockbuster sales on the line
Fierce Pharma
Blueprint Medicines
Ayvakit
FDA
systemic mastocytosis
Flag link:
Blueprint drug succeeds in rare disease study important to its market prospects
Blueprint drug succeeds in rare disease study important to its market prospects
BioPharma Dive
Blueprint Medicines
systemic mastocytosis
clinical trials
Ayvakit
Flag link:
Rare Blood Disease Drug Win Marks Fourth Approval for Blueprint Medicines
Rare Blood Disease Drug Win Marks Fourth Approval for Blueprint Medicines
BioSpace
Blueprint Medicines
Ayvakit
MCL
systemic mastocytosis
FDA
Flag link:
Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer
Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer
Endpoints
Blueprint Medicines
Roche
FDA
Ayvakit
Flag link:
FDA approval tracker: several early decisions in May
FDA approval tracker: several early decisions in May
EP Vantage
FDA
Deciphera
Qinlock
Blueprint Medicines
Ayvakit
Eli Lilly
Retevmo
Bristol-Myers Squibb
Opdivo
Yervoy
Flag link:
Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer
Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer
Fierce Pharma
Blueprint Medicines
Deciphera
FDA
GIST
Ayvakit
Qinlock
Flag link:
After a PhIII failure, the FDA delivers Blueprint an expected CRL
After a PhIII failure, the FDA delivers Blueprint an expected CRL
Endpoints
Blueprint Medicines
FDA
complete response letter
Ayvakit
gastrointestinal stromal tumors
Flag link:
Blueprint’s voyage ends in disaster
Blueprint’s voyage ends in disaster
EP Vantage
Blueprint Medicines
Ayvakit
clinical trials
Flag link:
The crucial data readouts coming soon for small biotechs
The crucial data readouts coming soon for small biotechs
EP Vantage
clinical trials
Akebia
Blueprint Medicines
Genfit
TG Therapeutics
vadadustat
Ayvakit
elafibranor
Flag link:
Blueprint gets first approval as FDA backs stomach cancer drug
Blueprint gets first approval as FDA backs stomach cancer drug
Pharmaforum
Blueprint Medicines
FDA
Ayvakit
stomach cancer
Flag link: